GlassScriptPhysician profile
Monique Sherman
NPI 1356073167
$2,107.77
in general payments reported to CMS, 2019-2025
23 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $994 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $513.27 | 2024-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $181.40 | 2024-2025 | Dupixent |
| Genzyme Corporation | $158.52 | 2024-2025 | |
| Electromed, INC. | $146.61 | 2024-2025 | Smartvest |
| Glaxosmithkline, LLC. | $144.38 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $141.29 | 2024-2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $93.36 | 2024-2025 | Acthar |
| Baxter Healthcare | $92.80 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $88.22 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $80.52 | 2024-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $66.21 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $62.80 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.98 | 2025 | |
| Amgen INC. | $55.30 | 2024-2025 | Tezspire, Tavneos |
| Lilly USA, LLC | $42.67 | 2025 | Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $27.08 | 2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $26.82 | 2024 | Opsumit |
| Genentech USA, INC. | $26.17 | 2025 | Xolair |
| Jazz Pharmaceuticals INC. | $26.07 | 2025 | |
| Inspire Medical Systems, INC. | $23.78 | 2025 | Inspire |
| Mylan Specialty L.P. | $21.15 | 2024 | Yupelri |
| Inogen, INC. | $19.46 | 2024 | |
| Philips North America LLC | $13.91 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.